Stenting works better for lipid-rich plaques — and now there's data to prove it

Not all coronary plaques are created equal, and a new analysis suggests that knowing a plaque's fat content could be the key to deciding who actually benefits from preventive stenting. Researchers analyzed data from the PREVENT trial — a randomized study of patients with non-flow-limiting vulnerable coronary plaques — to see whether lipid content changed the calculus on preventive percutaneous coronary intervention (PCI).

The findings were striking: patients with lipid-rich plaques had more than double the risk of cardiac events compared to those with non-lipid-rich plaques. But when preventive PCI was added to optimal medical therapy in the lipid-rich group, that elevated risk dropped dramatically — by 77%. Patients without lipid-rich plaques saw no meaningful benefit from the added procedure.

By the Numbers

• 37.3% of patients (223 out of 598) had lipid-rich plaques
• 12.5% vs. 4.7% — primary outcome event rates in lipid-rich vs. non-lipid-rich plaque patients
• 2.08x higher cardiac event risk in lipid-rich plaque patients
• 77% lower risk with preventive PCI + optimal medical therapy vs. medical therapy alone in lipid-rich patients
• Median follow-up: 5.6 years

Why it matters: These results suggest that plaque composition — not just anatomy — should guide preventive PCI decisions. Combining intravascular imaging with lipid content analysis could help cardiologists target stenting to the patients most likely to benefit, potentially avoiding unnecessary procedures in lower-risk patients.